VSC 4 SC AG

Ad hoc announcement in accordance with §15 WpHG [Securities Trading Act]

4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company, today announced the successful completion of a capital increase, after the Management Board, with the approval of the Supervisory Board, passed a resolution to authorise an increase of share capital on 23 October, 2009. The capital increase from the authorised capital included a collateral rights offering to existing shareholders at a subscription price of EUR3.00 per share. The remaining unsubscribed shares were allocated through a private placement in order to raise in the range of EUR25 to 30 million proceeds. The capital raising was completed at the top of the range and generated EUR30 million gross proceeds. The subscribed shares were not fully allocated.

The proceeds will be used to secure the further development of 4SC's current product pipeline. In particular, the focus will be on the further development of the Company's clinical compounds against auto-immune and cancer indications. Proof-of-concept is expected to be achieved within the next 24 months for the small molecule 4SC-101 in rheumatoid arthritis and the HDAC inhibitor 4SC-201 in hepatocellular carcinoma (liver cancer). In addition, preclinical projects will be developed to the stage where they can be advanced into the clinical pipeline, can provide further value generation and will ensure risk diversification in the Company's product portfolio.

Following the completion of the capital increase, a total of 10 million new shares were placed. As a result of the capital increase, 4SC AG's subscribed capital increased to EUR38,502,739.00. The free float will be approximately 19.02% of issued share capital. The approval of the new shares for trading at the Frankfurt Stock Exchange is expected in December 2009.

The capital increase was accompanied by Conrad Hinrich Donner Bank AG, Hamburg, Germany.

End of ad hoc notification

About 4SC

4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. The company currently has three clinical programs, with three further clinical trials planned to commence in 2009. 4SC-101, a small molecule, is in a Phase IIb study in rheumatoid arthritis as well as in a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, 4SC-201, a histone deacetylase (HDAC) inhibitor, is in a Phase II trial in hepatocellular carcinoma and is due to commence a further Phase II trial in Hodgkin's lymphoma in 2009. Drug candidates are developed until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.

4SC was founded in 1997, has 93 employees, and is listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

For further information please visit www.4sc.com.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

For more information please contact

4SC AG Yvonne Alexander, IR & PR Tel.: +49 (0) 89 70 07 63 66

MC Services (Europe) Stefan Riedel Tel.: +49 (0) 89 21 02 28 40

The Trout Group (USA) Chad Rubin Tel.: +1 646 378 2947

Language:  English
Company:   4SC AG
           Am Klopferspitz 19a
           82152 Martinsried
           Deutschland
Phone:     +49 (0)89 7007 63-0
Fax:       +49 (0)89 7007 63-29
E-mail:    public@4sc.com
Internet:  www.4sc.de
ISIN:      DE0005753818
WKN:       575381
Listed:    Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
           in Berlin, Düsseldorf, München, Stuttgart

4 SC (TG:VSC)
Historical Stock Chart
From Jan 2025 to Feb 2025

4 SC (TG:VSC)
Historical Stock Chart
From Feb 2024 to Feb 2025